All class III antiarrhythmic drugs share a common electrophysiological mechanism in that they prolong the action potential duration, and most of the drugs in this class do so primarily by inhibiting repolarizing potassium currents. Therefore, these compounds are often referred to as “potassium channel...
Antiarrhythmic drugs are often required. The targets, mechanisms and clinical guidelines are reviewed for common antiarrhythmic agents.doi:10.1016/j.mpaic.2018.04.009Hebbes ChristopherThompson Jonathan P.Anaesthesia & intensive care medicineDrugs acting on the heart : anti-arrhyth-mics. Wood M,Thompson...
Conversion of AF to sinus rhythm (SR) is possible using antiarrhythmic drugs. Amiodarone has a conversion rate in AF of up to 80%. A new drug for AF conversion is vernakalant. Acute therapy of atrial flutter (Aflut) in intensive care pts depends on the clinical presentation. It can most...
In this study, we explored the impact of antiarrhythmic drugs, known cation channel inhibitors, on the activated state of CAFs and their interaction with PCa cells. Methods The effect of antiarrhythmic treatment on CAF activated phenotype was assessed in terms of cell morphology and fibroblast ...
Ranolazine is classified as a Class ID compound because, unlike the Class I drugs, it blocks late sodium currents found during phase 2, which leads to a delay in the activation of repolarizing potassium channels in phase 3. Therefore, ranolazine increases the APD and ERP. ...
Volume 3, Issue 2, pages 129–130, April 1998 Additional Information How to Cite Akhtar, M. (1998), Invited Commentary on “Management of Idiopathic Ventricular Fibrillation: Implantable Defibrillators? Antiarrhythmic Drugs?”. Annals of Noninvasive Electrocardiology, 3: 129–130. doi: 10.1111/j....
Many drugs, including most antiarrhythmics (some of which are now of limited clinical use) are eliminated by the hepatic route. If liver function is impaired, it can be anticipated that hepatic clearance will be delayed, which can lead to more pronounced drug accumulation with multiple dosing. ...
Antiarrhythmic Drugsdoi:10.1016/j.mcna.2019.05.004Pranav MankadGautham KalahastyMedical Clinics of North America
Zipes DP (1987) Proarrhythmic effects of antiarrhythmic drugs. Am J Cardiol 59: 26E - 31E CrossRef Wyse DG (1991) Risk stratification: does it dermine who we should treat or how we should treat? J Cardiovasc Electrophysiol 2: 5205 Brugada P, Waldecker B (1986) Ventricular arrhythmias ...
Conclusions: Collectively, such data suggest a new therapeutic strategy for PCa based on the repositioning of antiarrhythmic drugs with the aim of normalizing CAF phenotype and creating a less permissive tumor microenvironment. 展开 关键词: PROSTATE cancer FIBROBLASTS PHENOTYPES CELL morphology EXTRACELLULAR...